Online inquiry

IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5892MR)

This product GTTS-WQ5892MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL31RA gene. The antibody can be applied in Atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001242636.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 133396
UniProt ID Q8NI17
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5892MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12910MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ11801MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ2966MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ11673MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ15371MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ7772MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ5760MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ984MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-368
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW